You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm has signed a three-year agreement with the University Hospital of Zurich to develop the test for use in kidney transplant recipients.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.
The company said it provided approximately 21,800 total AlloSure and AlloMap patient results during the quarter.
CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.
The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.
The viral assay, developed with Sentinel Diagnostics, improves the ability to monitor viral loads in critical organ transplant populations for the clinical management of infection.
The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.